Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Common Equity: 2011-2024

Historic Common Equity for Veracyte (VCYT) over the last 14 years, with Dec 2024 value amounting to $1.2 billion.

  • Veracyte's Common Equity rose 6.94% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 6.94%. This contributed to the annual value of $1.2 billion for FY2024, which is 12.63% up from last year.
  • Latest data reveals that Veracyte reported Common Equity of $1.2 billion as of FY2024, which was up 12.63% from $1.0 billion recorded in FY2023.
  • Veracyte's Common Equity's 5-year high stood at $1.2 billion during FY2024, with a 5-year trough of $421.2 million in FY2020.
  • Its 3-year average for Common Equity is $1.1 billion, with a median of $1.1 billion in 2022.
  • As far as peak fluctuations go, Veracyte's Common Equity spiked by 160.31% in 2021, and later dropped by 2.89% in 2023.
  • Yearly analysis of 5 years shows Veracyte's Common Equity stood at $421.2 million in 2020, then skyrocketed by 160.31% to $1.1 billion in 2021, then fell by 1.94% to $1.1 billion in 2022, then dropped by 2.89% to $1.0 billion in 2023, then climbed by 12.63% to $1.2 billion in 2024.